Investors Home

Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). 

The Company’s first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy

The Company is evaluating its investigational drug candidate EVO100 vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. In October 2020, Evofem initiated EVOGUARD, a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of EVO100 for the prevention of chlamydia and gonorrhea infection in women. Top-line results are expected in 2022.

EVOGUARD builds on reported positive, statistically significant top-line data from a double-blind placebo-controlled Phase 2b clinical trial (AMPREVENCE). This landmark study met its primary and secondary endpoints, demonstrating a 50% relative risk reduction in chlamydia infection and a 78% relative risk reduction in gonorrhea infection compared to placebo. AMPREVENCE results were presented at the 2020 STD Prevention Virtual Conference (view poster).

The Company has assembled a very strong management team with significant operational experience in the biopharmaceutical market. Specifically, our senior executives have a successful track record of developing and commercializing women’s health products including Mirena, Plan B One-Step, Yasmin, YAZ, NuvaRing, Paragard and Seasonique, among others.


Download Here: 

Evofem Investor Presentation 


Monday, November 23, 2020
10:00am EST

A virtual fireside chat with Evofem in advance of the Piper Sandler Virtual Healthcare Conference and investor meetings.

Nov 20, 2020

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place virtually November 30 through December 3,...

Nov 12, 2020

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the Stifel Virtual Healthcare Conference on Wednesday November 18, 2020 at 4:00 p.m. ET. To access the live and archived...

Nov 9, 2020

Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine- month periods ended September 30, 2020. "We are excited by the early...

Oct 27, 2020

Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the third quarter ended September 30, 2020 as...

Oct 26, 2020

Evofem Biosciences, Inc. (NASDAQ: EVFM) announced today that members of management will participate in a Virtual Investor KOL Roundtable on Thursday, October 29, 2020 at 2:00 p.m. ET. Saundra...

Read More